Additionally, the APCs derived from CCR2+HSCs uniquely cross-present tumor-derived antigens to both endogenous and adoptively transferred T lymphocytes, leading to prolonged T-cell activation within brain tumors and enhanced tumor rejection. This evidence concerns the gene CCR2 and neoplasm.